Literature DB >> 1182676

Evaluation of methotrexate in the treatment of bronchogenic carcinoma.

R G Vincent, J W Pickren, T B Fergen, H Takita.   

Abstract

One hundred ninety-five patients with disseminated bronchogenic carcinoma were treated with 10 different dosage schedules of methotrexate. Patient response to methotrexate therapy varied with the type of treatment, but overall, 18% of the patients treated responded to a measurable degree. Survival was not increased in any of the treatment categories when compared to a placebo group; however, the survival of patients that responded to therapy was greater than the survival of patients that did not respond to therapy. Methotrexate will find its greatest potential use in combination with other drugs proven to be effective in treating bronchogenic carcinoma.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1182676     DOI： 10.1002/1097-0142(197509)36:3<873::aid-cncr2820360308>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  9 in total

1.  Performance Status in Cancer: Not Broken, But Time for an Upgrade?

Authors:  Jessica M Scott; Guro Stene; Elisabeth Edvardsen; Lee W Jones
Journal:  J Clin Oncol       Date:  2020-06-25       Impact factor: 44.544

2.  Chemotherapy of non-small cell lung cancer: clinical trials at the Memorial Sloan-Kettering Cancer Center.

Authors:  R J Gralla; R E Wittes; E S Casper; D P Kelsen; E Cvitkovic; G B Magill; S E Krown; R B Golbey
Journal:  World J Surg       Date:  1981-09       Impact factor: 3.352

3.  The protein binding of methotrexate by the serum of normal subjects.

Authors:  W H Steele; J R Lawrence; J F Stuart; C A McNeill
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

4.  Cyclic alternating combination chemotherapy for small cell lung cancer.

Authors:  S K Reddy; H Takita; W W Lane; R G Vincent; T Y Chen; J E Caracandas; A M Regal
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Serum, tear and salivary concentrations of methotrexate in man.

Authors:  W H Steele; J F Stuart; B Whiting; J R Lawrence; K C Calman; J G McVie; G M Baird
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

Review 6.  Update in cancer chemotherapy, Part III: Lung cancer, Part 1.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1985-10       Impact factor: 1.798

7.  Comparison of intravenous and oral high-dose methotrexate in treatment of solid tumours.

Authors:  N Christophidis; F J Vajda; I Lucas; W J Moon; W J Louis
Journal:  Br Med J       Date:  1979-02-03

Review 8.  Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review.

Authors:  J B Sørensen; M Clerici; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Combination chemotherapy using high or low dose methotrexate for small cell carcinoma of the lung--a randomised trial.

Authors:  A M Arnold; C J Williams; G M Mead; R B Buchanan; J A Green; F M Macbeth; J M Whitehouse
Journal:  Med Oncol Tumor Pharmacother       Date:  1984
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.